Research in the field of stem cell therapy has exploded over the last few years. Stem cells are immature, unprogrammed cells that have the ability to grow into different kinds of tissue. Recent studies have shown that stem cell therapies offer real hope for the treatment of a wide range of diseases such as leukemia, diabetes, spinal cord injury, heart damage, brain damage, blood cell formation and even hair loss.
As a result of current findings, major initiatives are being conducted by large pharmaceutical and biotechnology companies, research establishments and universities around the world, to develop stem cell therapies in regenerative medicine. Unfortunately the demand for stem cells outstrips the supply. One of the bottlenecks in this rapidly expanding industry and ultimate commercialization is the ability to deliver sufficient supply of stem cells to advance these programs. Currently there are a vast number of stem cells lost in the process of cultivation, storage, transportation and recovery from cryopreservation.
ProtoKinetix reports that repeated tests have confirmed that the addition of AAG to the cryopreservation process more than doubles the useable inventory of these very delicate and valuable cells.
To contact one of our specialist lawyers please call 0800 61 66 81, or use the contact details at the top left of this page.
If you have a question about the information on this page
please
> click here
Others in a similar position reviewed the following pages:
To visit our most popular resources click here
Veteran F1 escapes shock shaft plunge with spinal injury
Spinal technology set to be developed under new partnership
Cenkos shareholder donates bonus to spinal injury charities
Bone mineral crystallisation study 'will support drug development'
Emulating athlete conditioning 'can reduce spinal injury risk'